Navigation Links
Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
Date:3/24/2008

SAN DIEGO, Calif., March 24 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of blood substitutes, today announced that it has completed enrollment in a Phase III trial of its lead product Hemospan(R).

The completed study of 460 patients is one of two parallel Phase III clinical trials being conducted at 36 academic medical centers in the United Kingdom, Sweden, the Netherlands, Belgium, Poland and the Czech Republic. The two randomized, placebo-controlled studies, which will enroll a combined total of more than 800 elective orthopedic surgery patients, are designed to evaluate the safety and efficacy of Hemospan in preventing and treating hemodynamic instability, especially hypotension, or low blood pressure, during surgery.

"We are pleased to have completed enrollment in this Phase III study," said Dr. Robert Winslow, Chairman, President and CEO of Sangart. "This represents a major milestone for Sangart as we continue to gather evidence of Hemospan's potential to satisfy the significant and growing demand for a safe and effective agent to improve oxygen transport in clinical settings where blood is often transfused."

Sangart also announced that enrollment in the second Phase III study is progressing well and is expected to be completed in the near future.

No similar oxygen transport agents are currently on the market in Europe or the United States. Earlier clinical studies indicate that Hemospan's novel oxygen delivery mechanism has the potential to provide a safe and effective alternative to blood transfusions.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
5. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
6. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
7. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
10. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
11. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... ALBANY, N.Y. , Aug. 31, 2015 /PRNewswire/ ... a.s. today announced a strategic collaboration focused on ... of opium-derived active pharmaceutical ingredients, ("APIs"). The collaboration ... biomass and their expertise in developing and manufacturing ... their ability to tech transfer processes into these ...
(Date:8/31/2015)... ADELAIDE, Australia , Aug. 31, 2015 ... the discovery and development of innovative therapeutics for the ... and cancer, today announced that its BNC101 IND submission ... Administration (FDA). Bionomics plans to initiate a Phase 1 ... in patients with metastatic pancreatic cancer prior to 31 ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... N.J., Sept. 20 Data from the GRACE ( G ... E xperience) study will be published in the September ... GRACE is the largest-ever study of treatment-experienced adult women with ... Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced today ... officer of Cytyc Corporation, has been elected to its ... including eight independent directors. "We are delighted ... board," said Hank Nordhoff, the Company,s chairman.  "We expect ...
Cached Medicine Technology:Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 2Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 3Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 4Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 5Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 6Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 7Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine 8Patrick J. Sullivan Elected to Gen-Probe Board of Directors 2
(Date:8/31/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... by Movestrong, has launched a new weight management program that is unique to ... highly recommended programs in Oakland and Macomb County. , WEmovestrong’s weight management ...
(Date:8/31/2015)... ... 31, 2015 , ... Patients who thought about getting a hair transplant but ... more about the procedure beyond the information found on the Internet can attend the ... Parsa Mohebi will be on hand to answer patients hair transplant questions at ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article published August 24th ... Global Open Journal that discusses the future of 3-D printing technology as it relates ... customized implants, prosthetics, and other 3-D printed tools could be used to aid in ...
(Date:8/31/2015)... ... ... Since 1946, the doctors and staff at Clifton Dental Associates have been ... at the office, the staff will make them feel welcome and comfortable. Drs. ... a complete dental treatment plan that is unique to each smile! NJ Top ...
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes ... comprehensive eye examination can diagnose amblyopia. According to the National Eye Institute ... 2 to 3 out of every 100 children. , Dr. Shofner adds, “unless ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... shown that they can deliver a gene directly into ... innovative, miniscule gene transport system, according to research published ... Pharmaceutics . Using a transport system called a ... School of Pharmacy, funded by Breast Cancer Campaign, packaged ...
... 70 and older have hearing loss, but those who are ... this loss, according to a new study led by Johns ... online Feb. 28 in the Journal of Gerontology: Medical Sciences, ... survey in older adults on this often ignored and underreported ...
... eve of finals and graduate students staring down a thesis ... obtaining an advanced education correlates with decades of lower blood ... researcher at Brown University. The benefit appears to be greater ... of community health, says the analysis of nearly 4,000 patient ...
... It is known that education decreases the incidence of ... access journal BMC Public Health demonstrates that ... a decrease in other factors which influence health such ... their data from The Framingham Offspring Study researchers followed ...
... , SATURDAY, Feb. 26 (HealthDay News) -- Armed ... far more muted response in the brains of depressed mothers ... a previous theory, "it looks as though depressed mothers are ... What we saw was really more of a lack of ...
... Dotinga HealthDay Reporter , FRIDAY, Feb. 25 (HealthDay ... a bit more daily exercise than teens without pooches, new ... directly leads to more active kids, but "there does still ... adolescent physical activity," said John Ronald Sirard, an assistant professor ...
Cached Medicine News:Health News:Gene fuelled transporter causes breast cancer cells to self-destruct 2Health News:Hearing loss rate in older adults climbs to more than 60 percent in national survey 2Health News:Advanced degrees add up to lower blood pressure 2Health News:Brain-Imaging in Depressed Moms Shows Blunted Response to Crying Infant 2Health News:Family Dog Might Make Teens More Active 2
... Flowmeters with brass and aluminum body., ... add suffix S to model number. ... add suffix C to model number. ... with Power Take-Off, add PT to ...
... Series Pediatric Oxygen Flowmeters with Double ... chain, add suffix S to model ... Color-Code, add suffix C to model ... Flowmeters with Power Take-Off, add PT ...
... FM Series Oxygen Adult Flowmeters, ... chain, add suffix S to ... For Canadian Color-Code, add suffix ... FM104C. , For Double Flowmeters ...
... American Proficiency Institute offers innovative proficiency ... technical support. As a result, API is ... in the world with over 12,000 laboratories ... advantages of using API:, Paperless ...
Medicine Products: